RCEL

AVITA Medical Inc

Add to Watchlist

Advanced Chart

5.920

+0.45(8.227%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.980

Open

5.460

VWAP

5.72

Vol

281.95K

Mkt Cap

157.55M

Low

5.300

Amount

1.61M

EV/EBITDA(TTM)

0.93

Total Shares

25.80M

171.84M

EV/OCF(TTM)

P/S(TTM)

1.91

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

19.33M

-1.23%

-0.268

-56.89%

21.18M

+14.75%

-0.238

-46.15%

23.29M

+26.07%

-0.130

-75.43%

Estimates Revision

The market is revising Downward the revenue expectations for AVITA Medical, Inc. (RCEL) for FY2025, with the revenue forecasts being adjusted by -21.07% over the past three months. During the same period, the stock price has changed by 15.18%.

Revenue Estimates for FY2025

Revise Downward

-21.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+610.12%

In Past 3 Month

Stock Price

Go Up

+15.18%

In Past 3 Month

4 Analyst Rating

39.36% Upside

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 8.25 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

1 Sell

Moderate Buy

39.36% Upside

Current: 5.920

Low

3.00

Averages

8.25

High

14.00

39.36% Upside

Current: 5.920

Low

3.00

Averages

8.25

High

14.00

Lake Street

Buy

downgrade

$14 -> $8

2025-08-11

Reason

Lake Street

Price Target

$14 -> $8

2025-08-11

downgrade

Buy

Reason

Lake Street assumed coverage of Avita Medical with a Buy rating and a price target of $8, down from $14. Although guidance was cut materially, the company reiterated confidence in a second half recovery and the firm views this as \"a prudent reset rather than a structural impairment,\" the analyst tells investors.

BTIG

Neutral -> Sell

downgrade

2025-08-08

Reason

BTIG

Price Target

2025-08-08

downgrade

Neutral -> Sell

Reason

BTIG downgraded Avita Medical to Sell from Neutral with a $3 price target. The company reported another quarterly miss and has reduced guidance in five of the last last quarters, the analyst tells investors in a research note. The firm believes Avita is in a \"very challenging position\" as reimbursement to providers via Medicare Administrative Contractors were not being paid despite submitting claims for usage through the the first half of 2025. BTIG sees Recell demand continuing to drop as providers avoid risk of not being paid. It believes the shares have downside risk as Avita works to remain solvent.

TD Cowen

Buy

downgrade

$15

2025-05-09

Reason

TD Cowen

Price Target

$15

2025-05-09

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Avita Medical to $12.50 from $15 and keeps a Buy rating on the shares. Avita reiterated its 2025 guidance despite reporting Q1 sales shy of Street expectations, notes the analyst, who contends that the next few quarters will be "a critical period" for key new growth drivers to gain traction.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$22

2025-04-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$22

2025-04-10

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$22

2025-04-04

Reason

D. Boral Capital

Jason Kolbert

Price Target

$22

2025-04-04

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$22

2025-03-18

Reason

D. Boral Capital

Jason Kolbert

Price Target

$22

2025-03-18

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for AVITA Medical Inc (RCEL.O) is -7.06, compared to its 5-year average forward P/E of -5.11. For a more detailed relative valuation and DCF analysis to assess AVITA Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.11

Current PE

-7.06

Overvalued PE

9.45

Undervalued PE

-19.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.59

Current EV/EBITDA

-7.82

Overvalued EV/EBITDA

106.22

Undervalued EV/EBITDA

-77.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.15

Current PS

1.89

Overvalued PS

12.77

Undervalued PS

1.53

Financials

Annual

Quarterly

FY2025Q2

YoY :

+21.21%

18.42M

Total Revenue

FY2025Q2

YoY :

-1516.33%

218.85M

Operating Profit

FY2025Q2

YoY :

-35.56%

-9.92M

Net Income after Tax

FY2025Q2

YoY :

-36.67%

-0.38

EPS - Diluted

FY2025Q2

YoY :

-30.32%

-10.75M

Free Cash Flow

FY2025Q2

YoY :

+1426.91%

1.33K

Gross Profit Margin - %

FY2025Q2

YoY :

-47.78%

-56.02

FCF Margin - %

FY2025Q2

YoY :

-46.83%

-53.86

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

113.7K

USD

Months

3-6

0.0

USD

Months

6-9

212.3K

USD

Months

0-12

18.5K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 534.61% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

113.7K

USD

Months

3-6

0.0

USD

Months

6-9

212.3K

USD

Months

0-12

18.5K

USD

Months

RCEL News & Events

Events Timeline

2025-09-04 (ET)

2025-09-04

07:50:36

Avita Medical Reports Data Indicating Decreased Hospital Stays with RCELL System

2025-08-12 (ET)

2025-08-12

08:34:06

Avita Medical completes Australian equity raise

2025-08-07 (ET)

2025-08-07

17:14:23

Avita Medical cuts FY25 revenue view to $76M-$81M from $100M-$106M

News

7.0

09-15Globenewswire

AVITA UPDATE: Bragar Eagel & Squire, P.C. Launches Investigation into AVITA Medical, Inc. for the Benefit of Stockholders and Urges Investors to Reach Out to the Firm

9.0

09-15SeekingAlpha

Avita Medical Shares Surge 10% Following CE Mark Approval for RECELL GO

7.0

09-10Globenewswire

INVESTOR NOTICE: Pomerantz Law Firm Probes Allegations for AVITA Medical, Inc. Investors - RCEL